The US-led Project Orbis initiative was used to authorize six new cancer medicines between 1 January and 5 December this year, while nine indication extensions were granted under the scheme. One medicine had its accelerated approval for a label expansion converted to a full marketing authorization.
One of the main aims of Project Orbis, which was established by the Food and Drug Administration in 2019, was...







